This Article Full Text Full Text (PDF) CME: Take the course for this article: Topotecan in the First-Line Treatment of Small Cell Lung Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, D. J. Search for Related Content PubMed PubMed Citation Articles by Stewart, D. J.

Topotecan in the First-Line Treatment of Small Cell Lung Cancer

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: David J. Stewart, F.R.C.P.C., The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC-9-3062, Houston, Texas 77030, USA. Telephone: 713-792-6363; Fax: 713-796-8655; e-mail: dstewart{at}mdanderson.org

Small cell lung cancer (SCLC) is generally sensitive to first-line chemotherapy, but limited disease often recurs and extensive disease is rarely curable. The most common first-line therapy regimen is cisplatin (Platinol^®; Bristol-Myers Squibb; Princeton, NJ) plus etoposide (Etopophos^®; Bristol-Myers Squibb)—PE, which is associated with overall response rates >80% in patients with limited SCLC. Although it is associated with median survival times of approximately 18–20 months for limited disease, PE yields median survival times of only approximately 8–12 months in patients with extensive disease, and symptom palliation becomes the primary therapeutic goal. The toxicities of PE may undermine quality of life and leave patients more susceptible to adverse events during subsequent therapies. Topotecan (HYCAMTIN^®; GlaxoSmithKline; Philadelphia, PA), an established treatment for recurrent SCLC, is being investigated in the first-line setting because of its novel mechanism of action; predictable, noncumulative, and manageable toxicities; and potential synergy with other active agents. Several recent phase II trials have generated promising results for topotecan-based combination regimens, including topotecan/paclitaxel (TAXOL^®; Bristol-Myers Squibb) (overall response rates 45%–100%), topotecan/etoposide (overall response, 95%), and topotecan, paclitaxel, and platinum agent triplets (overall response rates 51%–93%). The most frequent serious toxicity associated with these regimens was reversible and noncumulative neutropenia, which was generally manageable with supportive care. Additional clinical trials to investigate topotecan-based combination regimens and confirm their role in the first-line treatment of SCLC are under way.

Key Words. First-line • Pulmonary cancer • Small cell lung cancer • Topotecan

This article has been cited by other articles:

				D. A. Koster, F. Czerwinski, L. Halby, A. Crut, P. Vekhoff, K. Palle, P. B. Arimondo, and N. H. Dekker Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence Nucleic Acids Res., April 1, 2008; 36(7): 2301 - 2310. [Abstract] [Full Text] [PDF]

				E. R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and A. du Bois Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel J. Clin. Oncol., February 1, 2006; 24(4): 579 - 586. [Abstract] [Full Text] [PDF]

				D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis Oncologist, October 1, 2005; 10(9): 686 - 694. [Abstract] [Full Text] [PDF]

				R. T. Penson and M. V. Seiden Topotecan: Weighing in When There Are Many Options Oncologist, October 1, 2005; 10(9): 698 - 700. [Abstract] [Full Text] [PDF]

				T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]